New Horizons In Schizophrenia Research

This webinar reviews the latest developments in NIMHsponsored research including the recently announced Accelerating Medicines Partnership (AMP) Schizophrenia, a publicprivate partnership to advance the understanding of the risk factors for developing schizophrenia and promising new avenues for treatment. A number of novel treatment strategies for schizophrenia have shown promise, but changes in response have been a major challenge. One way to address this challenge is to identify biomarkers that may predict the course of the illness and assist in the design of clinical trials of new medications that can address the variability in treatment response. Dr. Lisanby reviews exciting developments underway related to largescale studies focused on identifying biomarkers of related to schizophrenia, with the longterm goal of leading to development of effective treatments and prevention strategies individualized for the needs of each person. To learn more about NAMIs Ask the Expert webinar